Pharmacology of laudanosine in dogs

The authors determined the pharmacokinetics (including transfer into cerebrospinal fluid [CSF]) and the cardiovascular and central nervous system (CNS) effects of laudanosine, a metabolite of atracurium. Eight dogs were anesthetized with halothane; blood pressure and a fronto-occipital electroencephalographic lead were monitored. Laudanosine (1 mg . kg-1 iv) was administered as a bolus, and its concentrations in plasma, CSF, urine, and bile were determined by liquid chromatography. Three-compartment modeling of plasma laudanosine concentrations yielded an elimination half-life for laudanosine of 113 +/- 24 min (mean +/- SD) and a clearance of 25 +/- 8 ml . kg-1 . min-1. CSF concentrations of laudanosine were highest 5-10 min after iv injection of laudanosine and ranged in concentration from 208 to 572 ng . ml-1 (i.e., 36-87% of the corresponding plasma concentrations). Unchanged laudanosine was found in urine (0.5-12% of injected dose) and bile (less than 0.1%); metabolites of laudanosine were found in both fluids. After a 6-h sampling period, dogs were hyperventilated with halothane (FIO2 = 0.2) to a PaCO2 of 26-28 mmHg. Laudanosine was then administered 2 mg . kg-1 iv every 5 min. With cumulative doses of 2-8 mg . kg-1, all dogs showed signs of "awakening" from anesthesia. Cumulative doses of 14-22 mg . kg-1 produced seizure activity in all animals. Mean arterial blood pressure decreased significantly to 86% of control levels at 1 min following administration of laudanosine (1 mg . kg-1 iv) and returned to control levels 4 min later.(ABSTRACT TRUNCATED AT 250 WORDS)     

科技进步与心血管病学的50年展望

本文主要阐述未来50年心血管病学领域内的各种进步,包括基因诊断和治疗、心脏外科手术的发展等等.     

Clinical significance and assessment of cytokines in various stages of ulcerative colitis

Summary In order to study the clinical significance and change of interleukin (IL)-1β and IL-10 concentration in intestinal mucosal tissues in various stage of ulcerative colitis (UC), IL-1β and IL10 levels were measured by enzyme linked immunosorbent assays (ELISA). Our results showed that IL-β level caused by spontaneous secretion in the intestinal mucous tissues in active stage of ulcerative colitis was significantly higher than that in normal controls and in remission stage of ulcerative colitis (P <0. 01,P<0. 001). IL-10 level in various stage of UC was relatively lower in controls, but there was no significantly difference between the two groups. Our study suggested that higher IL-1β level in active might play an important role in pathogenesis of UC, and IL-10, as an anti-inflammatory cytokine, was low in active UC, suggesting that it may be a important factor contributing to the development of higher IL-1β level. This project was supported by the grant of the Scientific Research Fund of the Ministry of Health (No. 98-2-387).     

多电极射频肿瘤治疗的体外实验研究

目的　了解射频消融灶大小与功率及时间的关系、超声与大体病理测值的关系、消融灶与周围组织的关系。方法　新鲜牛肝 3只和牛肾 2只 ,消融灶分两组 :距肝表面 1cm和 4cm ;同时将肾脏置于肝表面 ,用不同的功率和时间实验。结果　 10min时 ,2 0W ,40W ,6 0W ,80W的消融灶病理测值分别为 4.1cm ,3.8cm ,3.0cm ,3.3cm ,超声测值分别为 4.5cm ,4.0cm ,4.5cm ,4.0cm。 2 0min时 ,消融灶病理测值分别为 3.0cm ,4.1cm ,2 .8cm ,3.5cm ,超声测值分别为 4.3cm ,4.2cm ,3.4cm ,3.8cm。 30min时 ,消融灶病理测值分别为 3.5cm ,2 .9cm ,3.5cm ,3.4cm ,超声测值分别为 4.5cm ,4.0cm ,3.6cm ,4.1cm。超声和大体解剖测值相比 ,P <0 .0 1。消融灶和周围组织间有0 .3～ 0 .5cm的浅红色移行区。结论　射频消融灶的大小不随功率和时间的增加而增加 ,超声比大体病理测值大 ,两者差别有极显著性意义。消融病灶和周围组织间有移行区。浅表面的消融病灶对临近组织有损伤作用     

Safety and efficacy of ultrasound-guided low-pressure perfusion mini-percutaneous nephrolithotomy in children aged 1–7 years: a retrospective observational study

International Urology and Nephrology - This article analyzed the safety and efficacy of ultrasound-guided mini-percutaneous nephrolithotomy (MPCNL) with low-pressure perfusion for the treatment of...     

Comparison of efficacy and safety of daily oral L-arginine and PDE5Is alone or combination in treating erectile dysfunction: A systematic review and meta-analysis of randomised controlled trials

The meta-analysis was performed to assess the efficacy and safety of daily oral L-arginine and phosphodiesterase type 5 inhibitors (PDE5Is) alone or combination in treating patients with erectile dysfunction (ED). We performed a search of randomised controlled trials in the following databases: PubMed, EMBASE and Cochrane Library databases. Four articles including 373 patients were studied. Erectile functions were significantly improved in three therapy groups compared with baseline. Patients who received the combination of L-arginine and PDE5Is showed significant improvement compared to those treated with L-arginine and PDE5Is alone, as assessed by sexual function index (p <0.00001 and p =0.005, respectively) and total testosterone (p <0.00001 and p =0.0007, respectively). Furthermore, patients who treated with PDE5Is alone exhibited the better efficacy than those treated with L-arginine alone in respects of sexual function index (p <0.00001) and total testosterone (p =0.0001). However, the combination of L-arginine and PDE5Is had no obvious difference relative to PDE5Is alone in terms of various adverse events (AEs). Conclusively, compared with monotherapy, the combination of L-arginine and PDE5Is showed a greater improvement of sexual function and total testosterone, and did not significantly increase the AEs. Besides, PDE5Is alone revealed a better effect than those treated with L-arginine alone for patients with ED.     

The application of physical pretreatment in photodynamic therapy for skin diseases

Lasers in Medical Science - Photodynamic therapy (PDT) is widely used in skin diseases; the response rate of PDT treatment varies widely. The limited penetration in the tissue of photosensitizers...